Firm
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Matthew Grady of Wolf Greenfield says AI presents an opportunity in patent practice for stronger collaboration between in-house and outside counsel
Discussion hosted by Bird & Bird partners also hears that UK courts’ desire to determine FRAND rates could see the jurisdiction penalised in a similar way to China
Sponsored
Sponsored
-
Sponsored by Tilleke & GibbinsWaralee Sripawadkul of Tilleke & Gibbins says that the overturning of a decision on a trademark application by ExxonMobil could have a substantial impact in the area of non-traditional marks -
Sponsored by Tilleke & GibbinsLinh Thi Mai Nguyen and Chi Lan Dang of Tilleke & Gibbins summarise the main changes proposed under a draft decree on copyright and related rights in Vietnam
-
Sponsored by LexOrbisManisha Singh and Ritika Agarwal of LexOrbis analyse several recent rulings by the High Court of Delhi in appeals against decisions by the Registrar of Trademarks
-
Sponsored by Wanhuida Intellectual PropertyTiejun Tang, Yuming Wang, and Jianhui Li of Wanhuida Intellectual Property discuss the evolving landscape in China around ‘offering for sale’, with reference to a high-profile Supreme People’s Court case involving a patented drug
-
Sponsored by MaiwaldMarco Stief of Maiwald explains a ruling by the Düsseldorf Regional Court in the matter NuCana v Gilead that establishes the subsidiarity of the objection of disproportionality with regard to a compulsory licensing action
-
Sponsored by Patrinos & KilimirisConstantinos Kilimiris of Patrinos & Kilimiris explains why a ruling by the Athens First Instance Single Member Court is an important addition to the body of case law on the doctrine of equivalents
